Arcus Biosciences Inc (RCUS)
17.10
+0.66
(+3.98%)
USD |
NYSE |
Dec 04, 16:00
17.10
0.00 (0.00%)
After-Hours: 20:00
Arcus Biosciences Enterprise Value: 462.45M for Dec. 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| December 03, 2024 | 462.45M |
| December 02, 2024 | 416.69M |
| November 29, 2024 | 370.94M |
| November 27, 2024 | 403.88M |
| November 26, 2024 | 402.97M |
| November 25, 2024 | 290.41M |
| November 22, 2024 | 303.22M |
| November 21, 2024 | 264.79M |
| November 20, 2024 | 295.90M |
| November 19, 2024 | 285.83M |
| November 18, 2024 | 278.51M |
| November 15, 2024 | 394.73M |
| November 14, 2024 | 401.14M |
| November 13, 2024 | 461.54M |
| November 12, 2024 | 492.65M |
| November 11, 2024 | 582.33M |
| November 08, 2024 | 591.48M |
| November 07, 2024 | 464.28M |
| November 06, 2024 | 397.48M |
| November 05, 2024 | 357.21M |
| November 04, 2024 | 381.92M |
| November 01, 2024 | 376.43M |
| October 31, 2024 | 358.13M |
| October 30, 2024 | 422.19M |
| October 29, 2024 | 459.52M |
| Date | Value |
|---|---|
| October 28, 2024 | 482.39M |
| October 25, 2024 | 451.28M |
| October 24, 2024 | 589.44M |
| October 23, 2024 | 543.70M |
| October 22, 2024 | 495.20M |
| October 21, 2024 | 510.76M |
| October 18, 2024 | 645.26M |
| October 17, 2024 | 626.96M |
| October 16, 2024 | 592.19M |
| October 15, 2024 | 584.87M |
| October 14, 2024 | 613.24M |
| October 11, 2024 | 638.86M |
| October 10, 2024 | 522.65M |
| October 09, 2024 | 581.21M |
| October 08, 2024 | 556.50M |
| October 07, 2024 | 540.95M |
| October 04, 2024 | 481.48M |
| October 03, 2024 | 358.86M |
| October 02, 2024 | 366.18M |
| October 01, 2024 | 368.93M |
| September 30, 2024 | 357.04M |
| September 27, 2024 | 439.90M |
| September 26, 2024 | 438.07M |
| September 25, 2024 | 427.10M |
| September 24, 2024 | 457.27M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
22.18M
Minimum
May 11 2022
2.880B
Maximum
Nov 23 2021
888.87M
Average
677.39M
Median
Enterprise Value Benchmarks
| Merck & Co Inc | 281.24B |
| Regeneron Pharmaceuticals Inc | 74.56B |
| NovaBay Pharmaceuticals Inc | 2.076M |
| Palatin Technologies Inc | 18.73M |
| iBio Inc | 13.68M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -92.00M |
| Revenue (Quarterly) | 48.00M |
| Total Expenses (Quarterly) | 153.00M |
| EPS Diluted (Quarterly) | -1.00 |
| Profit Margin (Quarterly) | -191.7% |
| Earnings Yield | -18.43% |
| Normalized Earnings Yield | -17.07 |